Drug Type Monoclonal antibody |
Synonyms EPS 201, EPS-201 |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization Epsilogen Ltd.Startup |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Preclinical | GB | Epsilogen Ltd.Startup | 13 Mar 2022 |
Stomach Cancer | Preclinical | GB | Epsilogen Ltd.Startup | 13 Mar 2022 |